Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
CHAPEL HILL, N.C., April 06, 2016 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 15th Annual Needham and Company Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 1:40 p.m. ET on Wednesday, April 13, 2016 in New York City.
A live audio webcast and archive of the presentations will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
Contacts: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 [email protected] Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]
